Is There a Generic Version of Corlanor?
No, there is no FDA-approved generic version of Corlanor (ivabradine) available in the U.S. as of now. The brand-name drug, made by Amgen (formerly Servier), remains the only option on the market.[1]
When Does Corlanor Patent Protection End?
Corlanor's key U.S. patents expire between 2027 and 2030, including composition-of-matter and method-of-use protections listed on DrugPatentWatch. Pediatric exclusivity could push some dates to 2031. No generics are approved yet, but ANDA filings may emerge closer to expiry.[2]
What Is Holding Back Generic Approvals?
Multiple Orange Book-listed patents block generic entry until at least 2027. Amgen holds exclusivity tied to its New Drug Application (NDA 209964), approved in 2015 for heart failure. No Paragraph IV challenges have succeeded so far, delaying AB-rated equivalents.[2]
How Does Corlanor Compare to Similar Heart Drugs?
Corlanor reduces heart failure hospitalizations by slowing heart rate without affecting blood pressure. Alternatives include beta-blockers like metoprolol (generics available since 2001) or Entresto (sacubitril/valsartan, generics pending 2025 expiry). Ivabradine has no direct generic substitutes yet.[1][3]
Where Can Patients Get Corlanor or Savings Options?
Corlanor comes as 5mg or 7.5mg tablets. Patient assistance programs from Amgen or sites like NeedyMeds offer copay cards reducing costs to $25/month for eligible insured patients. Uninsured pricing averages $400–$500 for 60 tablets.[4]
Sources
[1] FDA Orange Book: https://www.accessdata.fda.gov/scripts/cder/ob/
[2] DrugPatentWatch.com: https://www.drugpatentwatch.com/p/tradename/CORLANOR
[3] Drugs.com: https://www.drugs.com/corlanor.html
[4] GoodRx: https://www.goodrx.com/corlanor